Drugs / BCMA/GPRC5D CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07032129 | Apr 2025 → Dec 2027 expected | plasma cell myeloma | Essen Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA/GPRC5D CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07032129 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T cell immunotherapy (CAR-T)” NCT07032129 ↗ |
| Route | Intravenous | “receive BCMA/GPRC5D CAR T cells intravenously (IV)” NCT07032129 ↗ |